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1. Introduction 
Calcified aortic stenosis is the most frequently reported valvular disease in our 
industrialized countries. This pathology is mainly observed in elderly patients with 3% 
prevalence after the age of 70. 
As a result of increasing life expectancy and the post war baby boom phenomenon, we can 
expect a “granny and granddad boom” in the years to come. Without surgical aortic valve 
replacement (SAVR), the prognosis of severe symptomatic aortic stenosis (AS) is poor and is 
associated with a short life expectancy after symptom onset (Bonow, Carabello et al. 2008). 
Although SAVR has been regarded as the gold standard treatment for severe AS for several 
decades (Bonow, Carabello et al. 2006; Vahanian, Baumgartner et al. 2007), many patients do 
not undergo surgical treatment as this therapeutic option is deemed to carry excessive risk 
by the patient’s family or by his physician, cardiologist or even the surgeon because of 
advanced age and the presence of co-morbidities. Indeed, many studies have shown that 
25% to 50% of symptomatic patients with severe AS do not receive surgical treatment. For 
instance, in the study by Iung et al. (Iung, Baron et al. 2003) 31.8% of eligible patients were 
not referred for SAVR. 
Balloon valvuloplasty (BAV) was introduced by Cribier et al in 1986, to support the concept 
of mechanical dilatation of severely calcified aortic valve (Cribier, Savin et al. 1986) for 
inoperable patients. Despite initial improvement of symptoms observed immediately after 
the procedure (NHLBI Balloon Valvuloplasty Registry Participant. 1991), it was associated 
with high mortality, complication and recurrence rates (Safian, Berman et al. 1988). Because 
of its poor long term outcome (about 50% survival at 1 year and 20% at 3 years) (Otto, 
Mickel et al. 1994; Lieberman, Bashore et al. 1995), this procedure  was performed in a 
dwindling number of cases, mainly as a bridge to SAVR in patients with poor hemodynamic 
status or in patients requiring urgent non cardiac surgery . 
Percutaneous catheter-based systems for the treatment of aortic valve stenosis were assessed 
in experimental animal models (Andersen, Knudsen et al. 1992) for several years before 
Cribier et al successfully designed a percutaneous transcatheter implantation system for an 
aortic valve prosthesis. They reported their first human case in 2002 using an antegrade 
transseptal approach with local anesthesia and mild sedation (Cribier, Eltchaninoff et al. 
2002). Subsequently, this system was developed by Edwards Lifesciences, for use via either 
a retrograde transfemoral approach (TF) with a new deflectable delivery system or a 
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transapical approach (TA). In 2004, Grube et al carried out the first-in-man percutaneous 
implantation of the CoreValve self-expanding valve prosthesis for severe AS and the initial 
experience of 25 cases was reported in 2005 (Grube, Laborde et al. 2006). Transcatheter aortic 
valve implantation (TAVI) is no longer an emerging technology for the treatment of patients 
with severe AS who are at high risk or ineligible for conventional surgery. It has become a 
valid treatment option addressing an unmet clinical need (Figure 1). TAVI and aortic 
valvuloplasty are now integrated into the potential therapeutic strategies applicable to 
patients with severe aortic stenosis carrying a high surgical risk and a heart team approach 
has become essential to implementing this procedure (Figure 2). 
 
 
Fig. 1. TAVI addresses an unmet clinical need 
 
 
Fig. 2. Heart team approach is essential for TAVI 
2. Clinical studies 
2.1 Cribier-Edwards, Edwards-Sapien valve 
The Edwards-Sapien (ES) valve is a trileaflet valve mounted on a balloon-expandable stent. 
The first-generation valve was made of polyurethane and the second-generation of bovine 
pericardium (Figure 3). After the pilot study involving six cases treated via the antegrade 
transvenous approach (Cribier, Eltchaninoff et al. 2004), initial feasibility studies (I-REVIVE 
and RECAST) were conducted in Rouen (Eltchaninoff, Tron et al. 2007) in 36 patients treated 
via both the antegrade and retrograde TF approaches. The retrograde delivery system was 
refined by Webb et al. and the results of the first 18 cases reported in 2006 showed improved 
procedural success and 30-day mortality (Webb, Chandavimol et al. 2006). 
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Fig. 3. The 1st generation Edwards valve 
Balloon expandable bioprothesis 
Stainless steel 
23, 26 mm 
Bovine pericardium 
Thermafix preparation 
Flex delivery system 
Retrograde or Trans-apical approach 
22 or 24 Fr femoral sheath  
The first procedure via the TA approach was performed in 2005 and the initial clinical 
experience was reported in 2006 (Lichtenstein, Cheung et al. 2006). CE Mark for both TF and 
TA delivery systems with the same valve was obtained for this device in 2007. In total, 9 
clinical trials and registries were completed from first-in-man to CE Mark. After CE Mark 
approval, a post-market registry (SOURCE) was conducted in Europe (Thomas, Schymik et 
al. 2010; Wendler, Schymik et al. 2010). In the United States, the PARTNER US trial (an FDA 
approved, two-cohort, four-arm multicenter trial with the second-generation Edwards 
valve) was initiated in 2007, and the results obtained in cohort B demonstrated that TF-TAVI 
not only reduces dramatically the risk of death from any cause compared to standard 
therapy (Leon, Smith et al. 2010), but also improves significantly the quality of life. The 
results of cohort A comparing TF / TA-TAVI with SAVR met the primary endpoint of the 
study, demonstrating the noninferiority of TAVI compared to conventional aortic valve 
replacement in terms of all-cause mortality (Smith and Leon 2011). At 30 days, deaths from 
any cause were numerically lower in the TAVI group by intention to treat (3.4% vs 6.5%), 
however, this was not statistically significant. At one-year follow-up, the mortality rate in 
both groups was nearly identical (24.2% vs 26.8%). The PARTNER 2 trial which has a similar 
design is currently assessing the third-generation Edwards valve. A comparable study 
evaluating the Corevalve is about to start in the United States. 
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2.2 Medtronic CoreValve revalving system 
The Medtronic CoreValve revalving system (Medtronic Inc., Minneapolis, MN, USA) is a 
trileaflet porcine pericardium valve mounted on a self-expanding nitinol frame. The first-in-
man clinical feasibility study (n = 14) was performed in 2004 with the first generation 25-Fr 
device. From 2005 to 2006, consecutive safety and efficacy studies (n = 65) were conducted 
using the second-generation 21-Fr device. The third-generation device (Figure 4) was 
developed in order to provide a lower profile system (18-Fr), which received CE Mark in 





Fig. 4. The CoreValve RevalvingTM System 
Self-expandable bioprothesis 
Nitinol  
26 and 29 mm 
Porcine Péricardium  
Retrograde approach 
18 Fr sheath 
3. Current devices and procedures 
3.1 Edwards Sapien XT valve 
3.1.1 Design 
The Edwards-Sapien valve has three bovine pericardium leaflets, mounted on a balloon-
expandable tubular frame with high radial force in order to obtain uniform leaflet 
coaptation and to maintain an effective orifice area. As with all surgical Edwards 
bioprostheses, the leaflets are prepared using the Thermafix technology. The stent of the last 
generation, SAPIEN XT, is made of a cobalt-chromium alloy (Figure 5), and the delivery 
system (Novaflex) has been improved in order to reduce the profile to 18 Fr for the 23 mm 
valve and 19 Fr for the 26 mm valve (the former retroflex delivery system was 22 and 24 Fr, 
respectively). A 29 mm valve has been recently introduced (only for the TA approach in 
2011) and a 20 mm valve will be available in the near future. 
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The two main approaches for the Edwards Sapiens valve are the TF and TA routes. Careful 
screening of the ilio-femoral access by CT scan and/or selective ilio-femoral angiography 
from different orthogonal planes is crucial for optimal selection of the approach site. The 
decision to proceed with TF approach depends on minimal lumen diameter, calcification 
 
 
Figure 5: The 2nd Generation Edwards: Sapiens XT valve : 
Balloon expandable bioprothesis  
Cobalt chromium 
23, 26, 29 mm  
Bovine pericardium 
Thermafix preparation 
Novaflex delivery system 
Retrograde and trans-apical approach 
18 or 19 Fr femoral sheath 
and tortuosity of ilio-femoral access, and presence of debris in the aorta. CT scan and/or 
transoesophagal echocardiography is an important part of the screening phase. The TA 
approach may be applied to patients with insufficient or risky vascular access. However, the 
presence of respiratory insufficiency or a hostile thorax must be taken into account. A novel, 
minimally invasive approach involving the direct puncture of the ascending aorta is 
currently being evaluated. 
The TF approach requires arterial access via the femoral artery by insertion of the sheath 
using direct puncture or surgical cut-down of the common femoral artery. The Novaflex 
delivery system is advanced through the sheath into the aorta. The Sapien XT valve is then 
mounted on the balloon in the aorta, by pulling back the balloon underneath the valve. The 
system is advanced into the annulus position whilst avoiding direct contact with the aorta 
using the flex system. The valve position should subsequently be confirmed by aortography 
from perpendicular projection and the valve should be deployed under rapid pacing (180 to 
240 beat/min.) in order to control blood pressure below 40 mmHg, and avoid migration of 
the valve during deployment. Closure of the femoral artery access is performed by ligation 
of the pre-deployed sutures of a Prostar XL device or two Proglide devices, or by surgical 
closure. In the early experience, surgical closure was adapted to the previously used 22- or 
24-fr sheaths. Gradual sheath down-sizing contributed to the generalization of the “true 
percutaneous approach” using direct puncture of the femoral artery and closure with a 
suture-mediated device (Kahlert, Al-Rashid et al. 2009; Van Mieghem, Nuis et al. 2010; 
Hayashida, Lefevre et al. 2011) as well as the possibility of using local anesthesia. 
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 TA-TAVI is performed using the current Ascendra 2 system inserted into the left ventricle 
(LV) via the apex. A double purse string is placed on the LV apex with mini anterior 
thoracotomy at the fifth or sixth intercostal space. The sheath is advanced into the LV cavity, 
followed by the insertion of the valve prosthesis after predilatation (Lichtenstein, Cheung et 
al. 2006). The valve is positioned under aortography guidance from a perpendicular 
projection and deployed with rapid pacing as in transfemoral procedures.  
3.2 Medtronic CoreValve revalving system 
3.2.1 Design 
The CoreValve revalving system is a self-expanding multilevel support frame with a tri-leaflet 
porcine pericardial tissue valve. A multilevel self-expandable Nitinol frame retains the tissue 
valve in place with high hoop strength. This high strength frame serves to preserve the 
anatomy of the valve, and stabilize the orifice area. The device is anchored by the high radial 
force area in the aortic annulus and by the low radial force area in the ascending aorta. 
This device is currently available in sizes of 26 mm for annuli of between 20 and 23 mm, 29 
mm for annuli between 23 and 27 mm. In the near future, a 32 mm valve will be available 
for annuli between 27 and 29 mm. 
The delivery system is an over-the-wire catheter system. The distal part of the catheter has 
an 18-fr housing capsule which contains the valve prosthesis, and both sizes of 
bioprostheses  can be accommodated by this delivery system. “The Accutrak delivery 
system” has been recently developed to reduce friction between the metal frame and the 
delivery system, thus preventing valve migration into the LV, and ensuring more accurate  
positioning of the bioprosthesis. 
3.2.2 Procedures 
This device can be implanted via three potential approaches: the TF, the transsubclavian, 
and the transaortic approaches. 
Like the Sapien valve, the Corevalve can be implanted via the TF approach  using an ilio-
femoral vascular access. The delivery system is advanced over a stiff wire into the LV cavity, 
with subsequent slow release of the bioprosthesis by turning the microknob under 
fluoroscopic guidance. Several aortographies should be performed to ensure that the valve 
is positioned correctly during deployment. 
The transsubclavian route is a potential alternative in cases where the femoral access is not 
sufficient. Surgical cut-down is performed for subclavian access, followed by sheath 
insertion into the ascending aorta. The delivery system is advanced to the aortic annulus as 
with the TF approach. This approach has been shown to be at least as safe as the TF 
approach in registries conducted in Italy and the UK (Petronio, De Carlo et al. 2010; 
Moynagh, Scott et al. 2011). 
The transaortic approach is implemented in patients in whom no other access options are 
available (Latsios, Gerckens et al. 2010). This approach requires a mini-sternotomy, and 
direct puncture of the ascending aorta under visual and fluoroscopic guidance (Latsios, 
Gerckens et al. 2010). The rest of the procedure is similar to the TF approach. 
The advantage of this self-expandable system is that it avoids traumatic dilatation of the 
annulus. The full retrievability of the bioprosthesis into the sheath is also advantageous in 
cases of valve migration before disconnection of the metal anchor of the frame from the 
delivery system. The relatively smaller delivery system is also beneficial for patients with a 
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4. Optimal patient selection 
Patients with symptomatic severe AS are considered candidates for TAVI if they have a high 
logistic EuroSCORE (European System for Cardiac Operative Risk Evaluation score) or STS 
score (the Society of Thoracic Surgeons Score), or if surgery is deemed to be of excessive risk 
due to significant comorbidities, or if other risk factors not captured by these scoring 
systems (eg, porcelain aorta, severe thoracic distortion, severe liver disease, pre-dialysis 
renal insufficiency etc…) are present. 
The decision to proceed with TAVI should be discussed by a dedicated heart team including 
cardiologists, interventional cardiologists, cardiovascular surgeons, anesthesiologists, and 
specialists in cardiac imaging. The role of geriatricians is crucial in borderline cases. The 
main concerns for optimal patient selection are: 1) annulus diameter of the native valve, 2) 
arterial access, and 3) diameter of the ascending aorta (Wenaweser and Windecker 2010). 
4.1 Annulus diameter 
4.1.1 Annulus size to define a valve prosthesis size 
Annulus size is a crucial parameter for selection of the appropriate type and size of valve. 
The annulus diameter criteria for Edwards valve are 18 to 21mm for the 23mm valve and 21 
to 24.5mm for the 26mm device. In 2011, a 29mm valve covering 24.5 to 27mm annuli has 
been launched for the TA approach exclusively. The 20mm valve is currently being 
developed. For the CoreValve, a 26mm valve is used for 20 to 23mm annuli and a 29mm 
valve for 23 to 27mm annuli (Grube, Schuler et al. 2007). A 32mm valve should be available 
in the near future. All currently available valves can be used to treat most patients with 
annulus sizes ranging from 18 to 27 mm. 
4.1.2 Imaging modalities for annulus diameter measurement 
Four modalities are available for measuring the aortic annulus: Transesophageal 
echocardiography (TEE), transthoracic echocardiography (TTE), invasive aortography and 
cardiac computed tomography (CT) scan (Wenaweser and Windecker 2010). TEE has been 
considered as the gold standard method for measuring the annulus size (Hutter, Opitz et al. 
2010), due to its better imaging quality compared to TTE and lower degree of inter-observer 




Fig. 6. MSCT and measurement of the annulus diameter 
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used for screening in order to exclude extremely small or large annuli or in instances where 
TEE is not applicable, due to its reduced imaging quality. Invasive aortography reflects the 
coronal view of the CT scan image. The fact that the aortic valve annulus is oval-shaped, 
rather than round-shaped must be taken into account when measuring the annulus size. CT 
scan is also a useful tool for measurement of the aortic annulus, providing appreciation of 
the oval shape of the annulus with high imaging quality. Due to its oval shape the annulus 
size measured by CT coronal view is larger than by sagital view (Schultz, Moelker et al. 
2010). 
One solution would be to measure the circumference or the surface of the annulus and use 
the theoretical diameter deducted from this measurement for selection of the valve (Figure 
6). TEE (Figure 7) or MSCT (Figure 8) assessment of the patient is essential in order to detect 
potential aortic debris which could preclude the use of the transfemoral route. 
 
 
Fig. 7. Transoesophagal echocardiography and aortic debris 
 
 
Fig. 8. MSCT and aortic debris 
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4.2 Arterial access 
The assessment of the ilio-femoral vessels can be performed by selective ilio-femoral 
angiography from 2 orthogonal planes, or multislice computed tomography (MSCT). Renal 
dysfunction is frequent in these patients and it is important not to cumulate several 
explorations requiring contrast media over a short period of time. For this reason we 
perform a selective angiogram of the ilio-femoral axes during coronary angiography. The 
radial approach is used preferentially in order to preserve any future femoral access for 
TAVI. MSCT is a useful tool for appraising the anatomy of the arterial access site. Such 
criteria as minimal lumen diameter (MLD), degree of calcification and tortuosity of the ilio-
femoral access are essential in determining patient eligibility for the TF approach. We 
established that the ratio between “sheath outer diameter” and “MLD of femoral artery” 
(SFAR) predicts the occurrence of major vascular complications and the cut-point of this 
ratio which best predicts vascular complications (Table 1) is 1.05 (Hayashida, Lefevre et al. 
2011). In non-calcified ilio-femoral vessels, the SFAR may be increased to 1.10 and 
conversely decreased to 1.00 in calcified arteries. Using this SFAR threshold, the minimal 
femoral artery diameter necessary for the 19 and 18 Fr introducer sheaths was calculated to 
be 6.8 and 6.5 mm respectively in non-calcified ilio-femoral vessels, and 7.5 and 7.2 mm 
respectively in calcified ilio-femoral vessels (Hayashida, Lefevre et al. 2011). While these 
measurements represent more restrictive criteria than previously recommended 
(Eltchaninoff, Kerkeni et al. 2009; Ducrocq, Francis et al. 2010; Tchetche, Dumonteil et al. 
2010; Thomas, Schymik et al. 2010), alternative approaches (TA, transthoracic, 
transsubclavian or retroperitoneal) should be considered in patients with borderline femoral 
artery diameters following careful vascular screening with selective ilio-femoral 
angiography or, if possible, MSCT. 
 
Sheath/Femoral artery ratio (SFAR) ≥ 1.05 (n = 55) < 1.05 (n = 72) p value  
Any vascular complication  23 (41.8%)  12 (16.7%)  < 0.001  
VARC Major  17 (30.9%)  5 (6.9%)  0.001  
VARC Minor  6 (10.9%)  7 (9.7%)  0.827  
Femoral artery complication  15 (27.3%)  9 (12.5%)  0.035  
Iliac artery complication  11 (20.0%)  2 (2.8%)  0.002  
30-day mortality  10 (18.2%)  3 (4.2%)  0.016  
Table 1. SFAR predict VARC major vascular complications 
4.3 Others 
Dimensions beyond 45 mm are considered to be an indication for replacement of the 
ascending aorta and constitute, therefore, a contraindication for CoreValve implantation, as 
the upper part of the frame supports the stability of the bioprosthesis. Recent myocardial 
infarction, severe pulmonary dysfunction (avoiding thoracotomy and intubation), and the 
presence of apical thrombus are considered contraindications for TA-TAVI. A bicuspid 
aortic valve is also considered a relative contraindication for TAVI. However, the annulus 
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size and anatomy (eccentricity index) which can be accurately assessed by MSCT is more 
important than the bicuspidity itself and some patients have been successfully treated using 
the Edwards valve or Corevalve (Wijesinghe, Ye et al. 2010). 
5. Complications, their management and avoidance 
Complications of TAVI can be classified as cardiac or non-cardiac. Appropriate patient 
selection, thorough knowledge of each device and well-mastered technique based on 
adequate experience are important to avoid these complications. 
5.1 Cardiac complications 
5.1.1 Aortic regurgitation 
Acute aortic regurgitation  
It may occur after balloon dilatation. This relatively rare complication is poorly tolerated 
and may lead to cardiogenic shock within a few minutes, so it is crucial to identify the 
problem and implant the valve as soon as possible. For this reason, the valve should always 
be ready at the time of balloon predilatation.  
Paravalular leak 
Though of no clinical consequence, minor paravalvular regurgitation is a common 
occurrence with current transcatheter valve devices. However, significant paravalvular 
regurgitation has been reported as an independent predictor of mortality between 30-day 
and 1-year in the Italian multicenter study of the CoreValve bioprosthesis (Tamburino, 
Capodanno et al. 2011). In the initial experience, significant paravalvular leaks were 
observed in many cases after implantation of the first-generation balloon-expandable 
bioprosthesis (Cribier, Eltchaninoff et al. 2002; Cribier, Eltchaninoff et al. 2004). However, 
the incidence of moderate to severe aortic regurgitation has been reduced in recipients of the 
Sapien or CoreValve bioprosthesis (Grube, Schuler et al. 2007; Walther, Simon et al. 2007; 
Webb, Pasupati et al. 2007) mainly by better screening of the annulus size and selection of 
over-sized valves. Low aortic diastolic pressure (40-50 mmHg) is the initial sign of significant 
aortic regurgitation. The causes of significant aortic regurgitation are; 1) undersizing of the 
valve due to underestimation of the annulus size, 2) incorrect positioning of the 
bioprosthesis, and 3) underexpansion of the valve. Bioprosthesis/annulus discordance was 
reported as an independent predictor of significant aortic regurgitation (Detaint, Lepage et 
al. 2009) thus annulus measurements and prosthesis sizing are critical in order to  avoid post 
procedure paravalvular leak. Correct positioning of the bioprosthesis can be achieved with 
increasing experience and technical enhancement of the device. Adequate long time 
inflation of the balloon (approximately 5 seconds) is recommended in order to avoid 
underexpansion of the balloon-expandable bioprosthesis. Optimal evaluation of 
paravalvular leak immediately after valve implantation is essential in order to address this 
issue during the procedure. In cases of significant paravalvular leak, post balloon dilatation 
using the same balloon with an extra 1 or 2 cc can be a useful option. However, the long-
term outcome of this procedure in terms of prosthesis durability is currently unknown. 
5.1.2 Valve malpositioning 
Valve positioning is one of the most challenging steps of the procedure, even with all 
necessary precautions and substantial operator experience. Valve migration after 
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deployment is generally the result of incorrect positioning or pacing failure leading to an 
effective ventricular contraction during deployment. In cases of valve migration into the 
aorta, the wire should be secured in order to keep the valve in a coaxial position and prevent 
it from flipping over and obstructing antegrade flow. The migrated valve can be positioned 
in the descending thoracic aorta by a partially inflated balloon or a goose-neck snare. 
However, care should be taken to avoid forceful repositioning of the valve as this may cause 
aortic dissection or rupture. 
5.1.3 Coronary occlusion 
Coronary occlusion may occur due to the shifting of the bulky calcified native leaflet toward 
the left main ostium. The main predictors are a short distance between the annulus and left 
main ostium, and small dimension of the sinus of Valsalva. It may also occur due to an 
excessively high implantation of the CoreValve, thouth this is a rare occurrence (<1%) in 
recipients of the Sapien as well as the CoreValve (Piazza, Grube et al. 2008; Lefevre, 
Kappetein et al. 2010). For the Sapien valve, preventive protection of the coronary ostium 
with a coronary guidewire and guiding catheter during TAVI may be effective in the 
presence of bulky calcified leaflets. Even though the presence of open cells over a coronary 
ostium is well-tolerated, selective coronary cannulation may prove difficult because of the 
stent struts jailing the coronary ostium. Preprocedural cardiac CT scan or aortography with 
simultaneous balloon valvuloplasty may help to detect any potential risk of coronary 
occlusion. A >10 mm distance between the annulus and the left main is recommended in 
order to avoid this complication (Wenaweser and Windecker 2010). 
5.1.4 Annulus and aortic root rupture 
Though rupture of the aortic annulus is an infrequently observed complication in TAVI 
(Himbert, Descoutures et al. 2009; Zajarias and Cribier 2009; Wendler, Schymik et al. 2010) 
as well as aortic valvuloplasty procedures (Hayes, Holmes et al. 1989), this complication 
(about 0.5%) can be fatal as it may rapidly result in cardiac tamponade and lead to 
catastrophic hemodynamic collapse in a few minutes. Excessive balloon dilatation, 
aggressive valve oversizing and extensive annular calcification may increase the incidence 
of this complication. Less aggressive balloon valvuloplasty and valve oversizing are 
recommended in the presence of markedly calcified annular and subannular tissues or an 
unusually small aortic root. 
5.1.5 Heart block 
Atrioventricular (AV) block is a known complication of surgical aortic valve replacement 
(Dawkins, Hobson et al. 2008) which occurs in 4 to 8% of cases. Heart block can also occur 
after TAVI, presumably due to continuous compression of the conduction system located in 
the LV outflow tract and interventricular septum. After Edwards valve implantation, AV 
block occurs in 2 to 7% of cases, usually immediately after the procedure (Piazza, Onuma et 
al. 2008; Vahanian, Alfieri et al. 2008). As the occurrence of AV block may be transient, it is 
recommended that pacemaker placement should not be considered until after 24 hours. 
The lower “skirt” structure of the CoreValve lies  within the left ventricular outflow tract 
and exerts continuous pressure on the left bundle branch (Khawaja, Rajani et al. 2011), 
leading to a subsequent new onset of left bundle branch block. The risk of AV block extends 
beyond the procedure duration up to day 4. Temporary pacemaker should be secured for at 
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least 48 hours and continuous monitoring for 4 days is recommended in patients who have 
not received a permanent pacemaker. When AV Block occurs during the procedure after 
Corevalve implantation, it is not necessary to wait for potential recovery as pacemaker 
implantation is a definite indication in such cases. Previous studies have reported a higher 
incidence of permanent pacemaker (PPM) implantation in recipients of the CoreValve (18% 
to 40%) (Jilaihawi, Chin et al. 2009; Khawaja, Rajani et al. 2011) compared to the Sapien 
valve (1.8% and 7.0%) (Sinhal, Altwegg et al. 2008; Godin, Eltchaninoff et al. 2010; Lefevre, 
Kappetein et al. 2010; Leon, Smith et al. 2010). Predictors of PPM requirement have been 
reported as periprocedural atrioventricular block, balloon predilatation, use of the larger (29 
mm) CoreValve prosthesis, interventricular septum diameter, prolonged QRS duration in 
the UK collaborative study (Khawaja, Rajani et al. 2011) and pre-existing right bundle 
branch block (Piazza, Onuma et al. 2008; Roten, Wenaweser et al. 2011). The main predictor 
seems to be the level of implantation of the valve into the left ventricle. 
Operators continue to endeavour to implant the valve in a relatively high position in order 
to reduce the risk of AVB. The new delivery system, Accutrak, should improve the accuracy 
of Corevalve deployment.  
5.1.6 Specific complications of TA approach 
Direct access to the left ventricle is obtained through an intercostal minithoracotomy and 
severe bleeding may occur at the end of the procedure. This seems to be related to technical 
problems during preparation of the access. Large deep stitches are recommended in order to 
avoid this problem. Apical pseudoaneurysm was reported as a specific complication of this 
approach (Masson, Kovac et al. 2009). Post procedural low-grade bleeding may result in 
cardiac tamponade and require further repair. Pleural effusion is also not uncommon. Mitral 
valve injury can also occur because of the nature of this procedure through the left ventricle. 
In some instances, the wire from the apex to the aorta can be pushed inadvertently behind 
the mitral chordae and create acute mitral regurgitation during manipulation of the 
introducer leading to cardiogenic shock. When identified, the problem is easily solved by 
pulling back the wire and rewiring the aorta whilst avoiding the mitral chordae.   
5.2 Non-cardiac complications 
5.2.1 Vascular complications 
Vascular complications are among the most frequent and serious complications of TF-TAVI, 
and have been associated with significantly increased patient morbidity and mortality 
(Webb, Chandavimol et al. 2006; Piazza, Grube et al. 2008; Rodes-Cabau, Webb et al. 2010). 
To date, vascular complications have been described in 8%-30.7% of Edwards valve 
recipients (Webb, Altwegg et al. 2009; Ducrocq, Francis et al. 2010; Lefevre, Kappetein et al. 
2010; Leon, Smith et al. 2010; Rodes-Cabau, Webb et al. 2010; Tchetche, Dumonteil et al. 
2010; Thomas, Schymik et al. 2010), and 1.9%-16% of CoreValve patients (Piazza, Grube et 
al. 2008; Bleiziffer, Ruge et al. 2009; Tchetche, Dumonteil et al. 2010; Van Mieghem, Nuis et 
al. 2010). In an effort to standardize the reporting of TAVI data, the Valve Academic 
Research Consortium (VARC) has recently developed a consensus on TAVI-related 
endpoints (Leon, Piazza et al. 2011), including a uniform definition of vascular 
complications. In our prospective series of TF-TAVI patients (85% Edwards and 15% 
Corevalve), we observed a vascular complication rate of 27.6% (VARC definition), including 
major vascular complications in 17.3% (Hayashida, Lefevre et al. 2011). We also found that 
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the occurrence of major vascular complications was a strong predictor of 30-day mortality 
(multiplying the risk of 30-day death by 4) and that major vascular complications were 
predicted by SFAR, center experience and the presence of femoral calcifications (Hayashida, 
Lefevre et al. 2011). Iliac perforation is a more severe potential vascular complication of TF-
TAVI, because it may lead to retroperitoneal hemorrhage and hemodynamic collapse. In our 
study, all iliac complications were classified as VARC major complications (Hayashida, 
Lefevre et al. 2011). Careful screening of vascular access and multimodality approach is 
crucial for selection of vascular access for TAVI. With technological advances, down-sizing 
of the device should be associated with further reductions in the risk of vascular 
complications in the future. 
5.2.2 Cerebro-vascular complications 
The incidence of clinically apparent cerebrovascular embolism (CE) complicated by TAVI is 
reported to be between 1.7% and 6.9% (Grube, Schuler et al. 2007; Webb, Pasupati et al. 2007; 
Webb, Altwegg et al. 2009; Rodes-Cabau, Webb et al. 2010; Thomas, Schymik et al. 2010). 
Two reports described a lower incidence of clinically apparent stroke in patients undergoing 
TA-TAVI compared to those with TF-TAVI (Bleiziffer, Ruge et al. 2009; Himbert, 
Descoutures et al. 2009). However, these findings have not been confirmed by other large 
studies (Table 2) including both TF and TA approaches (Webb, Altwegg et al. 2009; Kahlert, 
Knipp et al. 2010; Rodes-Cabau, Webb et al. 2010; Thomas, Schymik et al. 2010). 
 
Studies Stroke rate (%) Studies Stroke rate (%) 
PARTNER EU  TF 3.2 FRANCE Corevalve 4.5 








SOURCE TA 2.6 UK Registry Corevalve 4.0 




FRANCE TF 4.2 AVR high-risk*  2.8 
PARTNER US 6.9   
Belgian Registry 
Edwards 
3.1   
Table 2. Risk of Stroke after TAVI procedures  
In a study using diffusion-weighted magnetic resonance imaging (DW-MRI), TF-TAVI was 
associated with >70% incidence of new cerebral lesions following the procedure (Ghanem, 
Muller et al. 2010; Kahlert, Knipp et al. 2010) and there was also no difference between the 
TF and TA approaches (Rodes-Cabau, Webb et al. 2010). There are further data allowing 
comparison between TAVI and conventional SAVR (Kahlert, Knipp et al. 2010). Indeed, one 
report showed that despite a higher incidence of new foci of DW-MRI in the TAVI group 
(84% vs 48%, p = 0.011), the volumes of these lesions were significantly smaller after TAVI 
than after SAVR and no differences in clinically apparent stroke were evidenced. (Kahlert, 
Knipp et al. 2010). In the PARTNER US trial, a significant increase in any stroke was 
observed (5.5 vs 2.4%, p=0.04), but the combined endpoint of death or stroke at one year 
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were similar (26.5 vs 28.0% respectively). The etiologies of procedural stroke are likely to be 
atheroembolism from the ascending aorta or the aortic arch, calcific embolism from the 
aortic valve, thromboembolism from catheters, air embolism from LV cannulation, and 
prolonged hypotension. Repeated or overly aggressive valvuloplasty may be associated 
with an increased risk of embolization of calcific material from the aortic valve (Isner 1991) 
and should be avoided. 
5.2.3 Acute kidney injury 
Renal function and the development of acute kidney injury (AKI) are important factors 
influencing the outcome of patients after invasive procedures, such as percutaneous 
coronary intervention or cardiac surgery (Chertow, Levy et al. 1998; Lok, Austin et al. 2004). 
AKI has been observed in 12% to 28% of patients undergoing TAVI and is associated with a 
4-fold increase in post-procedural mortality (Aregger, Wenaweser et al. 2009; Bagur, Webb 
et al. 2010; Sinning, Ghanem et al. 2010). AKI after TAVI is related to an increased mortality 
risk in the short and mid-term, independent of whether renal function returns to baseline or 
not (Sinning, Ghanem et al. 2010). Although the mechanism of AKI after TAVI remains 
unknown, pre- and post-procedural impaired hemodynamics and hypotension caused by 
low ejection fraction, valvuloplasty and valve deployment, embolization of aortic debris 
during catheter manipulation, and amount of contrast media in these patients with poor 
renal function  may be among the main causes. 
6. Patient outcomes 
Procedural success rates have steadily improved from 82% (Cribier, Eltchaninoff et al. 2006) 
in the initial antegrade approach to more than 95% in recent reports of both available 
bioprostheses (Coeytaux, Williams et al. 2010; Yan, Cao et al. 2010). 
These data show that the procedure of TAVI is now reaching relative maturity. 
A review of the literature involving 84 reports on both bioprostheses, showed an overall 30-
day survival rate of 89% (Coeytaux, Williams et al. 2010). In the early reports of TAVI, 30-
day survival was around 50-60% in recipients of the Edwards valve (Cribier, Eltchaninoff et 
al. 2004; Cribier, Eltchaninoff et al. 2006). Increased operator experience and device 
enhancement may account for the recent improvements in the outcome of TAVI patients. In 
patients implanted with the Sapien valve, 30-day survival is currently between 88 and 94% 
via the TF approach (Webb, Pasupati et al. 2007; Lefevre, Kappetein et al. 2010; Rodes-
Cabau, Webb et al. 2010; Thomas, Schymik et al. 2010) and 81% to 92% via the TA route 
(Walther, Simon et al. 2007; Walther, Falk et al. 2008; Lefevre, Kappetein et al. 2010; Thomas, 
Schymik et al. 2010). 
In recipients of the CoreValve via the TF approach, 30-day survival is 89 to 93% (Grube, 
Buellesfeld et al. 2008; Piazza, Grube et al. 2008; Piazza, van Gameren et al. 2009; 
Tamburino, Capodanno et al. 2011). It is noteworthy that the recent publication of 2 
registries conducted in the UK and Italy in patients who underwent transsubclavian-TAVI 
using the CoreValve showed excellent short-term survival of 100% (Petronio, De Carlo et al. 
2010; Moynagh, Scott et al. 2011). These results require further confirmation in large 
prospective and controlled registries. 
The predictors of 30-day mortality are identified as logistic EuroSCORE, experience, low left 
ventricular ejection fraction, need for hemodynamic support during the procedure, 
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conversion to open heart surgery, cardiac tamponade, major vascular complication, acute 
kidney injury and diabetes mellitus,  (Wendler, Walther et al. 2010; Tamburino, Capodanno 
et al. 2011) 
Survival rates at 1 year ranging from 69 to 85% have been reported (Webb, Altwegg et al. 
2009; Coeytaux, Williams et al. 2010; Lefevre, Kappetein et al. 2010; Leon, Smith et al. 2010; 
Sinning, Ghanem et al. 2010; Yan, Cao et al. 2010). The predictors of late mortality are 
mainly related to comorbidities and reported as logistic EuroSCORE, STS score, age, severe 
mitral regurgitation, anemia, prior stroke, pulmonary disease, pulmonary hypertension, 
post procedural paravalvular leak ≥2, and chronic kidney disease (Walther, Simon et al. 
2007; Piazza, Grube et al. 2008; Himbert, Descoutures et al. 2009; Leon, Smith et al. 2010; 
Rodes-Cabau, Webb et al. 2010; Sinning, Ghanem et al. 2010). 
7. Valve performance 
The hemodynamic performance of the valve is very promising and seems so be superior to 
surgical valves with a lower gradient and larger valve area. In the cohort A of the PARNTER 
US trial (21) the valve area was 1.4+0.5 in the SAVR group compared to 1.6+0.5 (p=0.004) in 
the TAVI group. Paravalvular leak remains a problem which should be solved in the future. 
Mild to moderate aortic regurgitation was observed in 12% of cases in this study. 
8. Future perspectives 
8.1 Wider application of TAVI 
Until now, the indications for TAVI have been symptomatic severe AS with a EuroSCORE 
>20%, STS score >10% or instances where surgery is deemed to carry excessive risk due to 
significant comorbidities or contraindications. Recently, the results of the cohort B of the 
PARTNER US trial have demonstrated that, compared to standard medical therapy, TF-
TAVI using the Sapien valve significantly reduces the rates of death from any cause and 
repeat hospitalization (Leon, Smith et al. 2010). In this landmark study, TAVI treatment of 5 
patients resulted in one life being saved at one-year follow-up compared to medical 
treatment. The fact that one life was saved out of 5 patients treated is unparalleled in the 
history of medicine.  
The benefit of TAVI in terms of mortality was observed in all predefined subgroups (Figure 
9). Quality of life was also dramatically improved, as shown in Figure 10. Cohort A of this 
study comparing TF-TAVI vs conventional surgical aortic valve replacement (SAVR), and 
TA-TAVI vs SAVR has been recently published (Smith and Leon 2011) and demonstrated 
the noninferiority of TAVI compared to conventional aortic valve replacement in terms of 
all-cause mortality in high-risk patients. With respect to the CoreValve, SURTAVI, a 
multicenter, randomized clinical trial comparing the CoreValve with SAVR in patients with 
“intermediate” risk will start enrolling patients in Europe in 2011. PARTNER 2 will also 
explore the outcome of the third-generation Edwards valve in patients with intermediate 
risk in the United States. 
8.2 Valve in valve technique 
Percutaneous treatment of degenerated bioprostheses (Klaaborg, Egeblad et al. 2009; Webb, 
Wood et al. 2010) in patients at high risk for repeat surgery is currently being evaluated and 
seems very promising (Figure 11).  
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The consensus on TAVI-related endpoints published by the Valve Academic Research Consortium 
(VARC) (Leon, Piazza et al. 2011) should be useful for comparing new studies. 
Fig. 9. All-cause mortality in PARTNER US (Subgroup Analysis) 
 
 
* Improvement ≥ 10 points vs. baseline using Kansas City Cardiomyopathy Questionaire  
Fig. 10. Quality of life Improvement in PARTNER US* 
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Fig. 11. Valve in valve technique 
This new approach is likely to bring radical changes to the management of our patients in 
the years to come regarding which type of valve should be selected (mechanical or 
bioprosthesis) for conventional surgery. Indeed, the possibility of implanting a 
percutaneous valve in patients who have already received a surgical bioprosthesis may 
become a valid option. Currently, surgical bioprostheses have a 15- to 20-year durability. 
8.3 New devices 
A number of new devices are currently undergoing early clinical evaluation. The main 
improvement axes for enhancement of transcatheter valve technology are reduction in the 
delivery catheter size, a decrease in risks of paravalvular leaks, as well as facilitation of 
accurate positioning and retrieval (Low, Bolling et al. 2008; Schofer, Schluter et al. 2008; Falk, 
Schwammenthal et al. 2009; Treede, Tubler et al. 2010). The Sadra Lotus valve (Boston 
Scientific, USA), Direct Flow (Direct Flow Medical, USA), JenaClip (JenaValve, Germany), 
Engager (Medtronic, USA), St Jude (St Jude Medical, USA), Directflow and Symetis are 
examples of new valves. Although these valves have been the object of initial animal and 
even clinical studies, further evaluations in larger muticenter trials are needed. 
9. Conclusion 
The objective of this review was to describe state-of-the-art TAVI, as well as future 
perspectives. TAVI procedures are being carried out worldwide with encouraging results 
and reduced procedural risk and mortality. Although long-term data are required, short- 
and mid-term outcome of TAVI is comparable with that of conventional surgery in high-risk 
AS patients. As a result of increased experience and enhanced technology, TAVI is currently 
emerging as a new hope in our aging society for the growing number of elderly patients 
with severe AS. 
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